GnRHa

AcronymDefinition
GnRHaGonadotrophin Releasing Hormone Agonistic Analogue
References in periodicals archive ?
GnRHa injection accelerates final maturation and ovulation/ spermiation of sockeye salmon (Oncorhynchus nerka) in both fresh and salt water.
Gonadotropin releasing hormone analogues (GnRHa) also have been used to stimulate milt production in salmonids, increased milt volume or accelerated production of milt has been observed in response to GnRHa treatment (Weil and Crim, 1983).
A recent prospective, randomized, controlled clinical trial compared the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena) with a depot formulation of a GnRHa in the control of endometriosis-related chronic pelvic pain (CPP) in patients with severe endometriosis (50).
In 25 samples from women treated with GnRHa for 2 weeks, [E.
ER [alpha] ER [beta] Neonatal treatment Stroma Epithelium Stroma Epithelium Control + - +++ +++ DES 10 [micro]g +++ - +++ +++ EE ++ - +++ +++ Tamoxifen ++ - +++ +++ Bisphenol A + - +++ +++ Octylphenol + - +++ +++ Genistein + - +++ +++ GnRHa ++/+ - +++ +++ Flutamide ++ - +++ +++ AR PR Neonatal treatment Stroma Epithelium Stroma Epithelium Control +++ +++ - - DES 10 [micro]g + - +++ - EE ++ + ++ - Tamoxifen +++ +++ ++ - Bisphenol A +++ +++ - - Octylphenol +++ +++ - - Genistein +++ +++ - - GnRHa +++ +++ - - Flutamide ++ ++ ++ - Results are based on the semiquantification of sections from at least six animals per group (except for tamoxifen, where n = 3) and by comparison with sections from control and DES 10 [micro]g-treated animals.
The mechanism of thickening of the small arteriole walls in GnRHA treatment is interesting to speculate on.
de Dunkerque, F 59000 Lille, France (4) Nonstandard abbreviations: E2, estradiol; GnRHa, gonadoliberin agonist; IVF, in vitro fertilization; ET, embryo transfer; FSH, follitropin; HRT, hormone replacement therapy; tF, total number of follicles; rO, retrieved oocytes; to, fertilized oocytes; and F16, number of follicles with a diameter >16 mm.
Professor Shalet and his group discovered that children who were treated with GH and GnRHa achieved improved various growth parameters, which allowed many of the children to reach their target height.
Although the women in both the mid and high dose Progenta(TM) groups had fibroid reduction, as measured by ultrasound, numerically equivalent to or superior to the GnRHa, it should be cautioned that this was a small study.
Although the women in the high dose Progenta(TM) group have experienced fibroid reduction, as measured by ultrasound, numerically equivalent to or superior to the GnRHa, it should be cautioned that the effects of a GnRHa, which is approved for this indication, are best evaluated after at least three months of dosing.
At that time, women may elect to switch to the GnRHa for the duration of the study.
Women not experiencing a benefit with the study drug will be allowed to switch to the GnRHa for the duration of the study.